Evidence map›Paper›PMID 31217693›Full record

ArticleBiomarkers in cancer2019

Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor, Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial Growth Factor Levels, and the Systemic Symptoms like Capillary Leak Syndrome.

Havva Keskin, Kenan Cadirci, Ahmet Demirkazik, Hakan Akbulut, Bulent Yalcin

Open access · diamondAbstract read
In one paragraph

Article in Biomarkers in cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Havva KeskinDepartment of Internal Medicine, Istanbul Medeniyet University Training and Research Hospital, Istanbul, Turkey.ORCID https://orcid.org/0000-0003-1794-4473
Kenan CadirciDepartment of Internal Medicine, Erzurum Regional Training and Research Hospital, Erzurum, Turkey.
Ahmet DemirkazikDepartment of Medical Oncology, Faculty of Medicine, University of Ankara, Ankara, Turkey.
Hakan AkbulutDepartment of Medical Oncology, Faculty of Medicine, University of Ankara, Ankara, Turkey.
Bulent YalcinDepartment of Medical Oncology, Faculty of Medicine, University of Yildirim Beyazit and Atatürk Training and Research Hospital, Ankara, Turkey.
Ankara University · TRAnkara Yıldırım Beyazıt University · TRErzurum Regional Training and Research Hospital · TRIstanbul Medeniyet University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several problems such as myalgia, arthralgia, fever, dyspnea, generalized edema, and pleural effusion can occur in cancer patients following the chemotherapy, especially at the first cycle of the first chemotherapy treatment. Although it is assumed that some cytokines are associated with the development of these symptoms and signs, their pathophysiology has not been discovered completely yet. They are usually mild, but they may rarely progress to the severe stage of "Systemic Capillary Leak Syndrome" with a high mortality rate. The objective of this study was to investigate the association between the serum levels of interleukin-2 (IL-2), interleukin-11 (IL-11), tumor necrosis factor alpha (TNF-α), vascular endothelial growth factor (VEGF), and these symptoms and signs. A total of 44 cancer patients who had neither heart, lung, liver, renal, or thyroid disease were recruited into this study. Their symptoms and signs were examined and questioned before the first cycle of the first chemotherapy treatment and the 24 h after this chemotherapy. All participant's serum samples were taken, and the VEGF, TNF, IL-2, and IL-11 levels were studied. There was no association between the chemotherapeutic drugs, and the symptoms and signs such as edema, dyspnea, coughing, and flu-like symptoms. There was a significant decrease in IL-11 levels in the other treatment group compared with the group receiving paclitaxel, docetaxel, gemcitabine, and vinorelbine in the first day following chemotherapy (

Indexed as

capillary leak syndromeChemotherapyserum cytokinessystemic symptomsvascular endothelial growth factor

Identifiers

PMID31217693
PMCPMC6558530
OpenAlexW2952352234

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.